- Alirocumab, Praluent(R) in the light of studies2016 | First Faculty of Medicine
- The study ODYSSEY FH I and II with alirokumabem: other pieces in the mosaic of influences inhibition of PCSK92015 | First Faculty of Medicine
- The study ODYSSEY CHOICE I with alirocumab: more data on PCSK9 inhibition2017 | First Faculty of Medicine
- Turn in hypercholesterolemia treatment - PCSK9 inhibitors. What we know about the alirocumab (product Praluent(R)) yet?2016 | First Faculty of Medicine
- LDL-cholesterol: the lower the better! We need a new lipid lowering drugs? Focus on alirokumab (Praluent)2015 | First Faculty of Medicine
- Alirokumab2015 | Third Faculty of Medicine
- Alirokumab versus statiny v léčbě hyperlipidemie u nemocných s CKD : komentář2018 | First Faculty of Medicine
- Alirocumab in treatment of combined dyslipidemia2020 | Third Faculty of Medicine
- PCSK9 inhibition as the new hope for patients with familial hypercholesterolemia, statin intolerance and eventually for those at the highest cardiovascular risk? Focused on alirocumab, Praluent(R)2015 | First Faculty of Medicine
- First impressions of the ODYSSEY Outcomes trial2018 | First Faculty of Medicine
- Komentář: Alirokumab - významný přínos v léčbě pacientů s velmi vysokým nebo vysokým kardiovaskulárním rizikem2022 | First Faculty of Medicine
- The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?2018 | Faculty of Medicine in Hradec Králové
- Biologická léčba hypercholesterolemie2017 | First Faculty of Medicine
- Lipoprotein(a) - the cardiovascular risk factor: significance and therapeutic possibilities2018 | Faculty of Medicine in Hradec Králové
- Position of lipoprotein apheresis in present2015 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Aktuality ze světa inhibice PCSK92019 | First Faculty of Medicine
- PCSK-inhibitor in theory, in studies and in the real practice2019 | First Faculty of Medicine
- Comments on the most important and recent studies involving PCSK9i2018 | First Faculty of Medicine
- Nová chimérická molekula ACE2 Fc poskytuje dlouhodobou kontrolu hypertenze a ochranu orgánů u myších modelů systémové aktivace systému renin-angiotenzin : komentář2018 | First Faculty of Medicine
- Anotation of interesting articles from foreign literature2017 | First Faculty of Medicine
- PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated? Czech atherosclerosis society statement2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- An initiative to establish apheresis centers: indications for and performance of lipoprotein apheresis in the Czech Republic2019 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Nedostatečná korekce hodnot LDL cholesterolu u nemocných s periferní aterosklerózou: jak zlepšit tento stav?2022 | First Faculty of Medicine, Third Faculty of Medicine
- Fourier Study: Has it brought little or a lot of good? Or has it just failed to reach exaggerated expectations?2017 | First Faculty of Medicine